Information  X 
Enter a valid email address


  Print      Mail a friend

Friday 01 March, 2019


IXICO chosen for new Medical Imaging & AI Centre

RNS Number : 4991R
01 March 2019

1st March 2019



("IXICO" or the "Company")


IXICO chosen as partner for new Government funded Medical Imaging & Artificial Intelligence Centre


Led by King's College London, the centre aims to leverage UK research to improve the patient journey using artificial intelligence


IXICO plc (AIM: IXI), the data analytics company delivering insights in neuroscience, is delighted to announce that it has been chosen as a small-to-medium enterprise (SME) partner in the newly established London Medical Imaging & Artificial Intelligence Centre for Value-Based Healthcare.  With the official public launch having taken place yesterday (28th February), the centre has been established as part of the UK Government's Industrial Strategy Challenge Fund. Led by King's College London, the new Centre will develop and train sophisticated artificial intelligence (AI) algorithms from NHS medical images and patient data to provide tools for clinicians to speed up and improve diagnosis and care across a number of patient pathways including dementia, heart failure and cancer.


In order to achieve these results, the Centre brings together an ambitious consortium including London universities, NHS Trusts, industry partners including global multinationals and UK-based SME's and the Health Innovation Network.


The Centre will have a focus on transformation and value-based healthcare, and how advanced imaging and AI technologies can be used to improve the patient journey.  In addition to government funding, the consortia partners have also made significant investments to leverage UK research strengths and clinical knowledge into becoming a leading industrial player in AI and healthcare.  IXICO will contribute its expertise in neuroimaging and data analysis and benefit from leveraging the centre's unique infrastructure and collaborative framework to accelerate development of its innovative AI analytics solutions to support improved decision-making in neuroscience clinical development.


Giulio Cerroni, Chief Executive of IXICO, said: "We are excited to be selected to be part of this flagship UK Government initiative to ensure that UK science is at the forefront of the application and impact of Artificial Intelligence to the future of healthcare. The development and application of artificial intelligence technology will enable IXICO to develop highly valued, innovative solutions to our biopharmaceutical clients in support of their neuroscience clinical development programmes. We are looking forward to collaborations with other leaders across this expanding field of research."


For further information please contact:



Giulio Cerroni, Chief Executive Officer


Tel: +44 20 3763 7498

FTI Consulting Limited (Investor Relations)

Simon Conway / Victoria Foster Mitchell / Tim Stamper


Tel: +44 20 3727 1000



IXICO is dedicated to delivering insights in neuroscience. Our mission is to transform the progression of our biopharmaceutical clients' neurological therapeutic pipelines through the application of novel medical imaging and mobile health digital technologies.


IXICO's data analytics services are used by the global biopharmaceutical industry to interpret data from brain scans and digital biosensors to enable better trial design, site qualification, patient selection and clinical outcomes. We provide technology-enabled services across all phases of clinical evaluation. Our integrated digital platform provides a scalable and secure infrastructure for the capture and analysis of regulatory compliant clinical data to enable clients to make rapid, better informed decisions. IXICO is also collaborating with partners to develop new analytical techniques and companion digital health products targeted at improving patient outcomes.


More information is available on


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit

a d v e r t i s e m e n t